Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1

Status

Completed 5Terminated 4Unknown 2Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 17Gastrointestinal 14Thoracic 12Dermatologic 7Breast 7Head & Neck 6Gynecologic 6Lymphoid 4Tumor-Agnostic 2Sarcoma 2Other hematologic neoplasm 2CNS 2Plasma cell 1Other solid neoplasm 1

Conditions

Lymphoma 2Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hodgkin Disease 1Central Nervous System Neoplasms 1

Interventions

Rituximab 227Cyclophosphamide 142fludarabine 69Vincristine 66Methotrexate 62Doxorubicin 54fludarabine phosphate 53Lenalidomide 49Etoposide 49Cytarabine 48Prednisone 47Dexamethasone 44Filgrastim 43Bortezomib 38Whole-Body Irradiation 34Gemcitabine 34Melphalan 32Radiotherapy 30ibrutinib 29Granulocyte Colony-Stimulating Factor 29Alemtuzumab 29obinutuzumab 28Tacrolimus 28Mycophenolic Acid 28Antilymphocyte Serum 28venetoclax 27Calcium Dobesilate 27Busulfan 27Bendamustine Hydrochloride 27idelalisib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × avelumab × Lymphoid × Clear all
NCT03636503 2025-02-06

Rituximab + Immunotherapy in Follicular Lymphoma

Dana-Farber Cancer Institute

Phase 1 Terminated
24 enrolled 25 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT03451825 2024-06-24

Phase I/II Study of Avelumab in Pediatric Cancer Participants

EMD Serono

Phase 1 Terminated
21 enrolled 21 charts
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms

NCT02951156 2020-12-17

Javelin DLBCL

Pfizer

Phase 3 Terminated
29 enrolled 24 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02603419 2020-04-24

JAVELIN HODGKINS

Pfizer

Phase 1 Terminated
34 enrolled 43 charts
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡